Oral migraine treatment approved.
D000284:Administration, Oral; D000075202:Contraindications; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D011819:Rabies Vaccines / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014363:Tryptamines; D014481:United States; D014486:United States Food and Drug Administration
D010080:Oxazoles; D023303:Oxazolidinones; D011819:Rabies Vaccines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan